Dr. Gabriel Markson is an industry expert at Lilja Capital with a focus on healthcare. 

Gabriel is the co-founder of E3 Life AG, a lifescience investment and M&A advisory firm based in Zug, Switzerland. Since its inception, E3 Life has worked on multiple M&A processes in biotech and medtech, and is currently engaged in several lifescience investments together with large institutional investors in addition to raising its own investment fund.

Prior to founding E3 Life, he was an executive at the private equity owned medtech and pharma companies BSN medical (EQT), Gambro (EQT & Investor AB), and Nycomed (Nordic Capital). As an executive at these companies, Gabriel was responsible for strategy development and implementation including evaluating and executing multiple acquisitions in different geographies.

Gabriel is a former consultant with Cambridge Consultants and worked on multiple investments where he was involved in the commercial and technical due diligence of biopharma/biotech companies.

Gabriel completed his PhD in molecular biology at the MRC Human Genome Mapping Project and Cambridge Institute for Medical Research, Cambridge University, UK.